Role of IgG3 in Infectious Diseases

Trends in Immunology

Volumn 40, Issue 3, 2019, Pages 197-211

  Damelang, Timon ^a   Rogerson, Stephen J ^a   Kent, Stephen J ^a   Chung, Amy W ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

allotypes; antibody; antibody dependent cell cytotoxicity; complement; glycosylation; IgG3

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G; VACCINE;

ALLOTYPE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BACTERIAL INFECTION; COMPLEMENT ACTIVATION; DRUG MECHANISM; GLYCOSYLATION; HUMAN; NONHUMAN; PARASITOSIS; RECEPTOR BINDING; REVIEW; VIRUS INFECTION; ANIMAL; CELL PHAGOCYTOSIS; COMMUNICABLE DISEASE; COMMUNICABLE DISEASE CONTROL; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; METABOLISM; MOUSE;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; CYTOPHAGOCYTOSIS; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INFLAMMATION; MICE; VACCINES;

EID: 85061117062     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2019.01.005     Document Type: Review

References (121)

1. Ackerman, M.E., et al. Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control. PLoS Pathog., 12, 2016, e1005315.
2. Chung, A.W., et al. Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. Cell 163 (2015), 988–998.
3. Sadanand, S., et al. Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors. AIDS 32 (2018), 443–450.
4. Yates, N.L., et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci. Transl. Med., 19, 2014, 228.
5. Chung, A.W., et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med., 6, 2014, 228ra38.
6. Aase, A., et al. Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine. Scand. J. Immunol. 47 (1998), 388–396.
7. Vidarsson, G., et al. Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J. Immunol. 166 (2001), 6250–6656.
8. Giuntini, S., et al. Human IgG1, IgG3, and IgG3 hinge-truncated mutants show different protection capabilities against meningococci depending on the target antigen and epitope specificity. Clin. Vaccine Immunol. 23 (2016), 698–706.
9. Dechavanne, C., et al. Associations between an IgG3 polymorphism in the binding domain for FcRn, transplacental transfer of malaria-specific IgG3, and protection against Plasmodium falciparum malaria during infancy: a birth cohort study in Benin. PLoS Med., 14, 2017, e1002403.
10. Kana, I.H., et al. Cytophilic antibodies against key Plasmodium falciparum blood stage antigens contribute to protection against clinical malaria in a high transmission region of Eastern India. J. Infect. Dis. 218 (2018), 956–965.
11. Stanisic, D.I., et al. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect. Immun. 77 (2009), 1165–1174.
12. Weaver, R., et al. The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria. Sci. Rep., 6, 2016, 33094.
13. Osier, F.H.A., et al. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med., 12, 2014, 108.
14. Bruhns, P., Properties of mouse and human IgG receptors and their contribution to disease models. Blood 14 (2012), 5640–5649.
15. Chan, Y.N., et al. IgG binding characteristics of rhesus macaque FcgammaR. J. Immunol. 197 (2016), 2936–2947.
16. Trist, H.M., et al. Polymorphisms and interspecies differences of the activating and inhibitory Fc (RII of Macaca nemestrina influence the binding of human IgG subclasses. J. Immunol. 192 (2014), 792–803.
17. Lefranc, G., Lefranc, M.-P., The Immunoglobulin FactsBook. 2001, Academic Press.
18. Pumphrey, R.S.H., Computer models of the human immunoglobulins: Binding sites and molecular interactions. Immunol. Today 7 (1986), 206–211.
19. Carrasco, B., et al. Crystallohydrodynamics for solving the hydration problem for multi-domain proteins: open physiological conformations for human IgG. Biophys. Chem. 93 (2001), 181–196.
20. Vidarsson, G., et al. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol., 5, 2014.
21. Roux, K.H., et al. Flexibility of human IgG subclasses. J. Immunol. 159 (1997), 3372–3382.
22. Lefranc, M.-P., Lefranc, G., Human Gm, Km and Am allotypes and their molecular characterization: a remarkable demonstration of polymorphism. Methods Mol. Biol. 882 (2012), 635–680.
23. Stapleton, N.M., et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat. Commun., 2, 2011 Article number 599.
24. Rispens, T., et al. Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange. J. Biol. Chem. 289 (2014), 6098–6109.
25. Natsume, A., et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68 (2008), 3863–3872.
26. Van Loghem, E., et al. Staphylococcal protein A and human IgG subclasses and allotypes. Scand. J. Immunol. 15 (1982), 275–278.
27. Mahan, A.E., et al. Antigen-specific antibody glycosylation is regulated via vaccination. PLoS Pathog., 12, 2016, e1005456.
28. Gardinassi, L.G., et al. Clinical severity of visceral leishmaniasis is associated with changes in immunoglobulin G Fc N-glycosylation. mBio, 5, 2014 e01844-14.
29. van de Bovenkamp, F.S., et al. Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region. PNAS 115 (2018), 1901–1906.
30. Mimura, Y., et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol. Immunol. 37 (2000), 697–706.
31. Lee, C.-H., et al. IgG Fc domains that bind C1q but not effector Fcg receptors delineate the importance of complement-mediated effector functions. Nat. Immunol. 18 (2017), 889–898.
32. Lin, C.W., et al. A common glycan structure on immunoglobulin G for enhancement of effector functions. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 10611–10616.
33. Wang, T.T., et al. IgG antibodies to dengue enhanced for Fc(RIIIA binding determine disease severity. Science 355 (2017), 368–369.
34. Niwa, R., et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J. Immunol. Methods 306 (2005), 151–160.
35. Chung, A.W., et al. Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. AIDS 28 (2014), 2523–2530.
36. Ackerman, M.E., et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Investig. 123 (2013), 2183–2192.
37. Kaneko, Y., et al. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006), 670–673.
38. van de Bovenkamp, F.S., et al. Variable domain N-linked glycans acquired during antigen-specific immune responses can contribute to immunoglobulin G antibody stability. Front. Immunol., 9, 2018, 740.
39. Plomp, R., et al. Hinge-region O-glycosylation of human immunoglobulin G3 (IgG3). Mol. Cell. Proteomics 14 (2015), 1373–1384.
40. Julenius, K., et al. Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites. Glycobiology 15 (2005), 153–164.
41. Ferrante, A.L., et al. IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr. Infect. Dis. J., 9, 1990.
42. Schauer, U., et al. Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and Pneumococcal capsular polysaccharide in healthy children and adults. Clin. Diagn. Lab. Immunol. 10 (2003), 202–207.
43. Nouri-Aria, K.T., et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol. 172 (2004), 3252–3259.
44. Arnold, J.N., et al. Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol. Lett. 106 (2006), 103–110.
45. Malhotra, R., et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1 (1995), 237–243.
46. Lu, Y.L., et al. Solution conformation of wild-type and mutant IgG3 and IgG4 immunoglobulins using crystallohydrodynamics: possible implications for complement activation. Biophys. J. 93 (2007), 3733–3744.
47. Thommesen, J.F., et al. Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation. Mol. Immunol. 37 (2000), 995–1004.
48. Kapur, R., et al. IgG-effector functions: ‘The Good, The Bad and The Ugly’. Immunol. Lett. 160 (2014), 139–144.
49. Bruhns, P., et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113 (2009), 3716–3725.
50. Lu, L.L., et al. A functional role for antibodies in tuberculosis. Cell 167 (2016), 433–443.
51. McLean, M.R., et al. Dimeric Fc gamma receptor enzyme-linked immunosorbent assay to study HIV-specific antibodies: a new look into breadth of Fc gamma receptor antibodies induced by the RV144 Vaccine Trial. J. Immunol. 199 (2017), 816–826.
52. Chung, A.W., et al. Activation of NK cells by ADCC antibodies and HIV disease progression. J. Acquir. Immune Defic. Syndr. 58 (2011), 127–131.
53. Firan, M., et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of γ-globulin in humans. Int. Immunol. 13 (2001), 993–1002.
54. Shah, I.S., et al. Structural characterization of the Man5 glycoform of human IgG3 Fc. Mol. Immunol. 92 (2017), 28–37.
55. Einarsdottir, H., et al. H435-containing immunoglobulin G3 allotypes are transported efficiently across the human placenta: implications for alloantibody-mediated diseases of the newborn. Transfusion 54 (2014), 665–671.
56. Dugast, A.S., et al. Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur. J. Immunol. 44 (2014), 2925–2937.
57. Posadas-Mondragón, A., et al. Indices of anti-dengue immunoglobulin G subclasses in adult Mexican patients with febrile and hemorrhagic dengue in the acute phase. Mircobiol. Immunol. 61 (2017), 433–441.
58. Yates, N.L., et al. Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS 25 (2011), 2089–2097.
59. Horns, F., et al. Lineage tracing of human B cells reveals the in vivo landscape of human antibody class switching. eLife, 5, 2016, e16578.
60. Kitaura, K., et al. Different somatic hypermutation levels among antibody subclasses disclosed by a new next-generation sequencing-based antibody repertoire analysis. Front. Immunol., 8, 2017, 389.
61. Pene, J., et al. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J. Immunol. 172 (2004), 5154–5157.
62. Malisan, F., et al. Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes. J. Exp. Med. 183 (1996), 937–947.
63. Briere, F., et al. Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J. Exp. Med. 179 (1994), 757–762.
64. Fujieda, S., et al. IL-4 plus CD40 monoclonal antibody induces human B cells gamma subclass-specific isotype switch: switching to gamma 1, gamma 3, and gamma 4, but not gamma 2. J. Immunol. 155 (1995), 2318–2328.
65. Scharf, O., et al. Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1. J. Virol. 75 (2001), 6558–6565.
66. Richardson, S., et al. (2018) IgG3 hinge length enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. 2018, HIV Research for Prevention, Madrid.
67. Tay, M.Z., et al. Antibody-mediated internalization of infectious HIV-1 virions differs among antibody isotypes and subclasses. PLoS Pathog., 12, 2016, e1005817.
68. Kardava, L., et al. IgG3 regulates tissue-like memory B cells in HIV-infected individuals. Nat. Immunol. 19 (2018), 1001–1012.
69. Richardson, S.I., et al. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. PLoS Pathog., 14, 2018, e1006987.
70. Kam, Y.-W., et al. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with Chikungunya virus clearance and long-term clinical protection. J. Infect. Dis. 205 (2012), 1147–1154.
71. Syenina, A., et al. Dengue vascular leakage is augmented by mast cell degranulation mediated by immunoglobulin Fcγ receptors. eLife, 4, 2015, e05291.
72. Rodrigo, W.W., et al. Dengue virus neutralization is modulated by IgG antibody subclass and Fcγ receptor subtype. Virology 394 (2010), 175–182.
73. Ayala-Nunez, N.V., et al. How antibodies alter the cell entry pathway of dengue virus particles in macrophages. Sci. Rep., 6, 2016, 28768.
74. Wang, T.T., et al. IgG antibodies to dengue enhanced for FcgammaRIIIA binding determine disease severity. Science 355 (2017), 395–398.
75. Kuzmina, N.A., et al. Antibody-dependent enhancement of Ebola virus infection by human antibodies isolated from survivors. Cell Rep. 24 (2018), 1802–1815 e5.
76. Goh, Y.S., et al. Human IgG isotypes and activating Fcγ receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cells. Immunology 133 (2011), 74–83.
77. Sousa, A.O., et al. IgG subclass distribution of antibody responses to protein and polysaccharide mycobacterial antigens in leprosy and tuberculosis patients. Clin. Exp. Immunol. 111 (1998), 48–55.
78. Hussain, R., et al. PPD-specific IgG1 antibody subclass upregulate tumour necrosis factor expression in PPD-stimulated monocytes: possible link with disease pathogenesis in tuberculosis. Clin. Exp. Immunol. 119 (2000), 449–455.
79. Cai, Y., et al. Increased complement C1q level marks active disease in human tuberculosis. PLoS One, 9, 2014, 92340.
80. Richards, J.S., et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin. Infect. Dis. 51 (2010), 50–60.
81. Roussilhon, C., et al. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med., 4, 2007, e320.
82. Mathiesen, L., et al. Maternofetal trans-placental transport of recombinant IgG antibodies lacking effector functions. Blood 122 (2013), 1174–1181.
83. Stubbs, J., et al. Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies. Infect. Immun. 79 (2011), 1143–1152.
84. Boyle, M.J., et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity 42 (2015), 580–590.
85. Joos, C., et al. Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS One, 5, 2010, e9871.
86. Larsen, M.D., et al. Malaria parasite evasion of classical complement pathway attack. Mol. Immunol., 89, 2017, 159.
87. Kurtovic, L., et al. Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children. BMC Med., 16, 2018, 61.
88. Fernandez-Becerra, C., et al. Naturally-acquired humoral immune responses against the N- and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assay. Malar. J., 9, 2010.
89. Lima-Junior, J.C., et al. B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3alpha (PvMSP-3alpha) in malaria exposed individuals from Brazilian Amazon. Vaccine 29 (2011), 1801–1811.
90. Yilmaz, B., et al. Gut microbiota elicits a protective immune response against malaria transmission. Cell 159 (2014), 1277–1289.
91. Aguilar, R., et al. Antibody responses to α-Gal in African children vary with age and site and are associated with malaria protection. Sci. Rep., 8, 2018, 10.1038/s41598-018-28325-w Article number 9999.
92. Iriemenam, N.C., et al. Association between immunoglobulin GM and KM genotypes and placental malaria in HIV-1 negative and positive women in Western Kenya. PLoS One, 8, 2013, e53948.
93. Migot-Nabias, F., et al. Imbalanced distribution of GM immunoglobulin allotypes according to the clinical presentation of Plasmodium falciparum malaria in Beninese children. J. Infect. Dis. 198 (2008), 1892–1895.
94. Giha, H.A., et al. Antigen-specific influence of GM/KM allotypes on IgG isotypes and association of GM allotypes with susceptibility to Plasmodium falciparum malaria. Malar J., 8, 2009, 306.
95. Pandey, J.P., et al. Significant differences in GM allotype frequencies between two sympatric tribes with markedly differential susceptibility to malaria. Parasite Immunol. 29 (2007), 267–269.
96. Recke, A., et al. The p.arg435his variation of IgG3 with high affinity to FcRn is associated with susceptibility for pemphigus vulgaris – analysis of four different ethnic cohorts. Front. Immunol., 9, 2018, 1788.
97. Kaplon, H.K., Reichert, J.M., Antibodies to watch in 2019. 2018, MAbs.
98. Synagis (palivizumab). Full prescribing information, MedImmune, LLC, Gaithersburg, MD, 2014.
99. Mazumdar, S., Raxibacumab. MAbs 1 (2009), 531–538.
100. Weinheimer, S., et al. Ibalizumab susceptibility in patient HIV isolates resistant to antiretrovirals. 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018), Boston, USA, 2018.
101. Poiron, C. et al. (2010) IMGT/mAb-DB: The IMGT® database for therapeutic monoclonal antibodies. http://www.imgt.org/IMGTposters/SFI2010_IMGTmAb-DB.pdf.
102. Desoubeaux, G., et al. Therapeutic antibodies and infectious diseases. Tours, France, November 20–22, 2012. MAbs 5 (2013), 626–632.
103. Lakbub, J.C., et al. Disulfide bond characterization of endogenous IgG3 monoclonal antibodies using LC-MS: an investigation of IgG3 disulfide-mediated isoforms. Anal. Methods 8 (2016), 6045–6055.
104. Magdelaine-Beuzelin, C., et al. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet. Genomics 19 (2009), 383–387.
105. Bartelds, G.M., et al. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Res. Ther., 12, 2010, R221.
106. Webster, C.I., et al. A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors. MAbs 8 (2016), 253–263.
107. Ternant, D., et al. IgG1 allotypes influence the pharmacokinetics of therapeutic monoclonal antibodies through FcRn binding. J. Immunol. 196 (2016), 607–613.
108. Lazar, G.A., et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 4005–4010.
109. Moore, G.L., et al. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2 (2010), 181–189.
110. Huang, Y., et al. Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity. Cell 165 (2016), 1621–1631.
111. Mahlangu, J., et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N. Engl. J. Med. 379 (2018), 811–822.
112. Robb, M.L., et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect. Dis. 12 (2012), 531–537.
113. Cooper, P.J., et al. Human onchocerciasis and tetanus vaccination: impact on the postvaccination antitetanus antibody response. Infect. Immun. 67 (1999), 5951–5957.
114. Garcia, G., et al. Antibodies from patients with dengue viral infection mediate cellular cytotoxicity. J. Clin. Virol. 37 (2006), 53–57.
115. de Araujo, L.S., et al. IgG subclasses’ response to a set of mycobacterial antigens in different stages of Mycobacterium tuberculosis infection. Tuberculosis 108 (2018), 70–76.
116. Nimmerjahn, F., et al. Fc gamma RIV: a novel FcR with distinct IgG subclass specificity. Immunity 23 (2005), 41–51.
117. Murphy, A.J., et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. PNAS 111 (2014), 5153–5158.
118. Smith, P., et al. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 6181–6186.
119. Kana, I.H., et al. Naturally acquired antibodies target the glutamate-rich protein on intact merozoites and predict protection against febrile malaria. J. Infect. Dis. 215 (2017), 623–630.
120. Lefranc, M.P., et al. IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains. Dev. Comp. Immunol. 29 (2005), 185–203.
121. Lefranc, M.P., et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res, 37, 2009 D1006-12.